Activation of protein phosphatase 2A tumor suppressor as potential treatment of pancreatic cancer

作者：Chien Wenwen^*; Sun Qiao Yang; Lee Kian Leong; Ding Ling Wen; Wuensche Peer; Torres Fernandez Lucia A; Tan Siew Zhuan; Tokatly Itay; Zaiden Norazean; Poellinger Lorenz; Mori Seiichi; Yang Henry; Tyner Jeffrey W; Koeffler H Philip

来源：Molecular Oncology, 2015, 9(4): 889-905.

DOI：10.1016/j.molonc.2015.01.002

• PP2A
• Dasatinib
• Pancreatic cancer
• Phenothiazine
• FTY-720

We utilized three tiers of screening to identify novel therapeutic agents for pancreatic cancers. First, we analyzed 14 pancreatic cancer cell lines against a panel of 66 small-molecule kinase inhibitors and dasatinib was the most potent. Second, we performed RNA expression analysis on 3 dasatinib-resistant and 3 dasatinib sensitive pancreatic cancer cell lines to profile their gene expression. Third, gene profiling data was integrated with the Connectivity Map database to search for potential drugs. Thioridazine was one of the top ranking small molecules with highly negative enrichment. Thioridazine and its family members of phenothiazine including penfluridol caused pancreatic cancer cell death and affected protein expression levels of molecules involved in cell cycle regulation, apoptosis, and multiple kinase activities. This family of drugs causes activation of protein phosphatase 2 (PP2A). The drug FTY-720 (activator of PP2A) induced apoptosis of pancreatic cancer cells. Silencing catalytic unit of PP2A rendered pancreatic cancer cells resistant to penfluridol. Our observations suggest potential therapeutic use of penfluridol or similar agent associated with activation of PP2A in pancreatic cancers.

• 出版日期2015-4